Latest Product Launch News

Biome Australia has secured ethics approval to commence a pivotal human clinical trial of its proprietary probiotic strain BMB18, aiming to validate its benefits on digestive, sleep, and mood health.

Nuchev Limited reported a 19% decline in Q2 FY26 sales revenue, with steady retail performance in its Oli6® brand offset by a sharp drop in the Practitioner channel. The company remains debt-free and is advancing new product development to drive future growth.

Tissue Repair’s December quarter update reveals a cautious path forward for its Phase 3 TR987 trial amid slow patient recruitment, while its TR Pro+ product line gains momentum through a new distributor partnership and upcoming product launches.

Cann Group Limited has reported its first-ever free cash flow positive quarter, following a significant debt restructuring and a $9 million capital raise. Despite a softer quarterly revenue, the company is advancing new product launches and export partnerships, positioning itself for growth.

One Click Group Limited has reported a robust 28% increase in revenue for 2025 alongside a significant expansion in its user base and the rollout of an upgraded cash advance product. The fintech’s strategic focus on growth and innovation sets the stage for a promising 2026.

The Calmer Co has posted a record $2.01 million in sales for Q2 FY26, propelled by a 9% increase in US revenue which now accounts for over half of the group’s total income. Strong retail and wholesale growth underpin the company’s expanding footprint in the natural relaxation market.

The Calmer Co. International Limited has reported a second consecutive quarter of revenue exceeding $2 million, driven by strong U.S. growth and record monthly sales in December. The company’s strategic focus on wholesale and B2B extract channels underpins its confidence in reaching breakeven this fiscal year.

Spectur Limited reported a 4.5% increase in quarterly revenue to $2.02 million and secured $2.15 million through a share placement to fund its AI-driven Sense-Think-Act platform development.

Little Green Pharma reports record quarterly revenue and announces a transformative merger with Cannatrek, creating a leading vertically integrated medicinal cannabis group with strong European growth prospects.

Mayne Pharma delivered a robust FY25 performance with a 105% surge in underlying EBITDA and launched key dermatology products as it outlines a strategic growth path for FY26.

ikeGPS Group has reported a robust 35% increase in its platform subscription revenue exit run rate for the nine months to December 2025, reaffirming its FY26 growth guidance amid strong market demand and new AI-driven product launches.

Firebrick Pharma has commenced commercial manufacturing and export of its new Nasodine Throat Spray, marking a significant step in its international expansion. The company also reported a 15% increase in cash sales and reduced operating costs, signalling improving financial health.